Management of Platelet Disorders and Platelet Transfusions in ICU Patients

Transfus Med Rev. 2017 Oct;31(4):252-257. doi: 10.1016/j.tmrv.2017.04.002. Epub 2017 May 4.

Abstract

Thrombocytopenia or receipt of antiplatelet drugs, with or without bleeding, is a common indication for platelet transfusions in the ICU. However, there is almost no evidence base for these practices other than expert opinion. Also common is use of platelet transfusions prior to invasive procedures or surgery in patients with thrombocytopenia. Likewise, there is no high-quality evidence that such practices are efficacious or safe. Recently, it has become clear that, whether causal or not, patients receiving prophylactic platelet transfusions experience high rates of nosocomial infection, thrombosis, organ failure, and mortality, which increase the urgency and need for randomized trials to assess these practices. Investigational methods of improving the safety and efficacy of platelet transfusions include use of alternate strategies such as antifibrinolytics; use of ABO-identical, leukoreduced, and washed platelet transfusions; and improved storage solutions.

Keywords: Intensive care; Platelet transfusion; Thrombocytopenia.

Publication types

  • Review

MeSH terms

  • Antifibrinolytic Agents / therapeutic use
  • Blood Platelet Disorders / blood
  • Blood Platelet Disorders / therapy*
  • Humans
  • Intensive Care Units*
  • Platelet Transfusion* / methods
  • Platelet Transfusion* / statistics & numerical data
  • Thrombocytopenia / blood
  • Thrombocytopenia / therapy

Substances

  • Antifibrinolytic Agents